Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Haematologica|February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
Cancer Medicine|December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapyLouise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 12, 2020
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working PartyAli Bazarbachi, Myriam Labopin, Emanuele Angelucci, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 4, 2021
Factors associated with coinfections in invasive aspergillosis: a retrospective cohort studyFrançois Danion, Céline Duval, François Séverac, et al.
Journal of Hematology & Oncology|January 7, 2024
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registryClaire Lacan, Jérôme Lambert, Edouard Forcade, et al.
NEJM Evidence|June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML TherapyMathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
European Journal of Haematology|March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trialAnne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2022
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life ExperienceVincent Marmouset, Justine Decroocq, Sylvain Garciaz, et al.
Blood|May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapyNicolas Duployez, Romane Joudinaud, Augustin Boudry, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
Pageof 2